Comments on: ASGCT Conference 2026 – Atamyo Therapeutics presents promising results in the first patients treated with its ATA-200 gene therapy in the clinical trial targeting LGMD-R5 limb-girdle muscular dystrophy

Comments on: ASGCT Conference 2026 – Atamyo Therapeutics presents promising results in the first patients treated with its ATA-200 gene therapy in the clinical trial targeting LGMD-R5 limb-girdle muscular dystrophy https://atamyo.com/press-releases/2026/asgct-conference-2026-atamyo-therapeutics-presents-promising-results-in-the-first-patients-treated-with-its-ata-200-gene-therapy-in-the-clinical-trial-targeting-lgmd-r5-limb-girdle-muscular-dystroph/ Changing life of Neuromuscular patients Thu, 14 May 2026 07:41:35 +0000 hourly 1 https://wordpress.org/?v=6.7.5